Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.72 |
| ▸ | LYN | P07948 | 3/20 | 0.72 |
| ▸ | LCK | P06239 | 3/20 | 0.72 |
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | TEC | P42680 | 3/20 | 0.70 |
| ▸ | BMX | P51813 | 3/20 | 0.70 |
| ▸ | ITK | Q08881 | 3/20 | 0.70 |
| ▸ | TXK | P42681 | 2/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | BLK | P51451 | 2/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.70 |
| ▸ | LATS1 | O95835 | 1/20 | 0.70 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | CSF1R | P07333 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458820 | 1.00 | BTK (0.72) | BTKLYNLCKEGFRTEC | |
| SCHEMBL16075646 | 0.91 | BTK (0.77) | BTKLYNLCKEGFRTEC | |
| SCHEMBL27801461 | 0.90 | BTK (0.72) | BTKLYNLCKEGFRTEC | |
| SCHEMBL4910818 | 0.89 | BTK (0.79) | BTKLYNLCKEGFRTEC | |
| SCHEMBL21898176 | 0.86 | BTK (0.80) | BTKLYNLCKEGFRTEC | |
| SCHEMBL18608117 | 0.86 | BTK (0.80) | BTKLYNLCKEGFRTEC | |
| SCHEMBL25068925 | 0.85 | BTK (0.80) | BTKLYNLCKEGFRTEC | |
| SCHEMBL19230350 | 0.85 | BTK (0.78) | BTKLYNLCKEGFRTEC | |
| SCHEMBL18235474 | 0.85 | BTK (0.78) | BTKLYNLCKEGFRTEC | |
| SCHEMBL22737178 | 0.85 | BTK (0.80) | BTKLYNLCKEGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414248-A1 | PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB | AZAD Pharmaceutical Ingredients AG (CH) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137446-A1 | PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2017-08-17 | — | — | WO | claimed |
| EP-2526934-B1 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2024119111-A2 | MORPHIC FORMS OF A MUTANT BRAF DEGRADER AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2022117731-A9 | ELECTROSTATIC NANOPARTICLES AND USE THEREOF | Westfälische Wilhelms-Universität Münster (DE) | 2024-05-16 | — | — | WO | disclosed |
| EP-4340889-A1 | ANTIBODY-PROTAMINE FUSIONS AS TARGETING COMPOUNDS OF A PROTAMINE-BASED NANOPARTICLE | Universität Münster (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023220655-A1 | METHODS TO OVERCOME DRUG RESISTANCE BY RE-SENSITIZING CANCER CELLS TO TREATMENT WITH A PRIOR THERAPY VIA TREATMENT WITH A T CELL THERAPY | CELGENE CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4255496-A1 | ELECTROSTATIC NANOPARTICLES AND USE THEREOF | Westfälische Wilhelms-Universität Münster (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20230158030-A1 | METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023034336-A2 | IMPROVED TREATMENTS FOR ADVANCED/METASTATIC CANCERS WITH CHECKPOINT INHIBITOR RESISTANCE OR RESISTANCE SUSCEPTIBILITY | G1 THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022117731-A1 | ELECTROSTATIC NANOPARTICLES AND USE THEREOF | Westfälische Wilhelms-Universität Münster (DE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2017040617-A1 | BTK INHIBITOR COMBINATIONS FOR TREATING MULTIPLE MYELOMA | PHARMACYCLICS LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016207172-A1 | PREPARATION OF PURE AMORPHOUS IBRUTINIB | SANDOZ GMBH (AT) | 2016-12-29 | — | — | WO | disclosed |
| EP-3076975-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016160598-A1 | SOLVATED FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016160604-A1 | CO-CRYSTALS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016106381-A1 | BTK INHIBITOR COMBINATIONS AND DOSING REGIMEN | PHARMACYCLICS LLC (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016081460-A1 | TLR INHIBITOR AND BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS | PHARMACYCLICS LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016029175-A1 | METHODS FOR TREATING EGFR MUTANT DISORDERS | PHARMACYCLICS LLC (US) | 2016-02-25 | — | — | WO | disclosed |
| WO-2015084857-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158030-A1 | METHODS AND COMPOSITION FOR TREATMENT OF COVID-19 ILLNESS REQUIRING HOSPITALIZATION | IL15, IL6, IL2 | BTK 4/4885LYN 53/4885LCK 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.